Wholesale-Drugs, Proprietaries & Druggists' Sundries
11 listed companies the SEC classes under this industry (code 5122), in order of revenue.
11 of them have annual figures on record. The 11 reporting in US dollars had revenue of $985.6B between them in their latest fiscal years.
| Company | Fiscal year to | |||
|---|---|---|---|---|
| McKesson Corp | Mar 2026 | $403.4B | $4.76B | $82.3B |
| Cencora, Inc. | Sep 2025 | $321.3B | $1.55B | $76.6B |
| Cardinal Health Inc | Jun 2026 | $254.2B | $1.71B | $57.3B |
| Herbalife Ltd. | Dec 2025 | $5.04B | $228.3M | $2.79B |
| NU Skin Enterprises, Inc. | Dec 2025 | $1.49B | $160.2M | $1.41B |
| Cosmos Health Inc. | Dec 2025 | $65.3M | −$19.1M | $65.5M |
| DataMeds AI, Inc. | Dec 2025 | $23.3M | −$101.3M | $30.5M |
| Cellyan Biotechnology Co., Ltd | Mar 2025 | $20.3M | −$27.1K | $9.42M |
| Stemtech Corp | Dec 2025 | $2.88M | −$4.05M | $3.15M |
| Can B Corp | Dec 2023 | $2.16M | −$9.74M | $10.1M |
| EnerSyn Global Inc. | Dec 2025 | $866.9K | −$2.63M | $4.57M |
Each company's latest fiscal year, as its annual report to the SEC gave the figures; the year links to that report. Amounts in other currencies are not converted, and sort after those in dollars.